Formosa Pharmaceuticals, Inc. (TPE:6838)
Taiwan · Delayed Price · Currency is TWD 29.95
+0.45 (1.53%)
At close: Jan 19, 2026
Formosa Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
| 12.16 | 143.36 | 31.17 | 1.32 | 28.53 | - | Upgrade | |
Revenue Growth (YoY) | -91.15% | 359.89% | 2270.49% | -95.39% | - | - | Upgrade |
Cost of Revenue | 11.61 | 24.37 | 3.83 | 0.98 | 0.27 | - | Upgrade |
Gross Profit | 0.55 | 118.99 | 27.35 | 0.33 | 28.26 | - | Upgrade |
Selling, General & Admin | 47.68 | 60.8 | 40.2 | 25.53 | 20.65 | 17.31 | Upgrade |
Research & Development | 112.39 | 226 | 270.18 | 356.47 | 387.62 | 216.29 | Upgrade |
Operating Expenses | 167.88 | 294.62 | 310.38 | 382 | 408.27 | 233.6 | Upgrade |
Operating Income | -167.33 | -175.63 | -283.04 | -381.67 | -380.01 | -233.6 | Upgrade |
Interest Expense | -0.48 | -0.57 | -4.31 | -0.99 | -2.21 | -0.1 | Upgrade |
Interest & Investment Income | 25.92 | 21.18 | 12.42 | 0.47 | 0.06 | 0.48 | Upgrade |
Currency Exchange Gain (Loss) | 18.95 | -18.62 | 9.29 | -25.15 | 20.97 | 14.04 | Upgrade |
Other Non Operating Income (Expenses) | 50.07 | 1.03 | 0.09 | 0.75 | 0.01 | -0.25 | Upgrade |
EBT Excluding Unusual Items | -72.88 | -172.61 | -265.54 | -406.59 | -361.18 | -219.43 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | - | - | -0.2 | -0.72 | Upgrade |
Other Unusual Items | - | -6.96 | -34.53 | - | -37.04 | - | Upgrade |
Pretax Income | -72.88 | -179.57 | -300.07 | -406.59 | -398.42 | -220.15 | Upgrade |
Income Tax Expense | 1.35 | 21.36 | 21.86 | -0.42 | 2.4 | -0.42 | Upgrade |
Earnings From Continuing Operations | -74.23 | -200.93 | -321.93 | -406.17 | -400.82 | -219.73 | Upgrade |
Minority Interest in Earnings | -0.02 | -0.08 | -0.03 | -0.1 | -0.06 | 0.07 | Upgrade |
Net Income | -74.25 | -201.01 | -321.96 | -406.27 | -400.88 | -219.66 | Upgrade |
Net Income to Common | -74.25 | -201.01 | -321.96 | -406.27 | -400.88 | -219.66 | Upgrade |
Shares Outstanding (Basic) | 149 | 141 | 124 | 105 | 92 | 71 | Upgrade |
Shares Outstanding (Diluted) | 149 | 141 | 124 | 105 | 92 | 71 | Upgrade |
Shares Change (YoY) | 7.04% | 13.48% | 18.00% | 13.70% | 31.19% | 8.70% | Upgrade |
EPS (Basic) | -0.50 | -1.43 | -2.59 | -3.86 | -4.33 | -3.12 | Upgrade |
EPS (Diluted) | -0.50 | -1.43 | -2.59 | -3.86 | -4.33 | -3.12 | Upgrade |
Free Cash Flow | -56.01 | -135.95 | -198.21 | -346.15 | -331.35 | -180.4 | Upgrade |
Free Cash Flow Per Share | -0.38 | -0.96 | -1.60 | -3.29 | -3.58 | -2.56 | Upgrade |
Gross Margin | 4.52% | 83.00% | 87.73% | 25.32% | 99.06% | - | Upgrade |
Operating Margin | -1375.65% | -122.51% | -907.98% | -29024.26% | -1332.01% | - | Upgrade |
Profit Margin | -610.38% | -140.22% | -1032.84% | -30895.21% | -1405.18% | - | Upgrade |
Free Cash Flow Margin | -460.47% | -94.83% | -635.85% | -26323.19% | -1161.46% | - | Upgrade |
EBITDA | -127.61 | -139.99 | -247.53 | -345.56 | -345.41 | -200.58 | Upgrade |
EBITDA Margin | - | -97.65% | - | - | - | - | Upgrade |
D&A For EBITDA | 39.72 | 35.64 | 35.51 | 36.11 | 34.6 | 33.02 | Upgrade |
EBIT | -167.33 | -175.63 | -283.04 | -381.67 | -380.01 | -233.6 | Upgrade |
EBIT Margin | - | -122.51% | - | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.